Pharming Group N.V. Sponsored ADR (PHAR) – What Are Researchers Thinking About This Stock?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has earned a consensus rating of “Hold” from the five research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $39.67.

PHAR has been the subject of several research reports. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, October 23rd. Weiss Ratings upgraded shares of Pharming Group from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, October 27th. Wall Street Zen upgraded shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Sunday. Canaccord Genuity Group lifted their price target on Pharming Group from $38.00 to $41.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Finally, Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Wednesday, October 28th.

Pharming Group Trading Up 4.1%

NASDAQ:PHAR opened at $12.73 on Tuesday. The business has a fifty day moving average of $10.73 and a 200-day moving average of $13.77. The stock has a market cap of $901.00 million, a price-to-earnings ratio of 39.78 and a beta of -0.05. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.31 and a current ratio of 3.23. Pharming Group has a 1 year low of $9.11 and a 1 year high of $21.34.

Pharming Group (NASDAQ:PHAR) last released its earnings results on Tuesday, October 27th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.21 by $0.09. Pharming Group had a net margin of 6.23% and a return on equity of 8.70%. The firm had revenue of $117.60 million for the quarter, compared to analysts’ expectations of $117.60 million. Equities analysts predict that Pharming Group will post 0.34 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP bought a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises approximately 6.0% of MAC Alpha Capital Management LP’s investment portfolio, making the stock its 2nd biggest holding. MAC Alpha Capital Management LP owned 3.03% of Pharming Group at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.